<div id="readability-page-1">Bioventus (BVS) is up  ~19% in Tuesday trading after posting Q3 financial results that beat on both lines.  While net sales change year-over-year was essentially flat due to a ~29% decline in its restorative therapies segment, the medical device company saw strong growth of, respectively, 6.4% and 9.3%, in its two largest businesses, pain treatment...</div>

<p>Bioventus (BVS) 的股價在發佈第三季度財報後上漲了約 19%，該財報超出了預期。儘管由於修復療法部門大幅下降 29%，導致同比淨銷售額變化持平，但公司在其兩個最大領域——疼痛治療和另一個未指明的領域——分別實現了 6.4% 和 9.3% 的顯著增長</p>

Bioventus 因第三季度業績超出預期而股價飆升